Sign in →

Test Code PECRA Preeclampsia sFlt-1/PIGF Ratio

Important Note

This test is for inpatient testing ONLY for pregnant women, with singleton pregnancies (gestational age 23+0 to 34+6/7 weeks) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension), within 2 weeks of presentation.

Specimen and Container/Tube

Specimen Type: Serum

Preferred Specimen: Plain Red Top

Other Acceptable specimens: Serum (SST, Gold Top), Plasma (K2-EDTA, Purple Top)

Specimen Handling and Transport Instructions

UCMC Onsite Instructions: 

Send specimen to laboratory at Room Temperature.

 

UCMC Offsite and UC MedLab Outreach Instructions: 

Not Applicable - this test is for In-Patient use ONLY

Rejection Criteria

  • Common specimen rejected situations include: incorrect specimen type, insufficient volume, missing or incomplete specimen identifiers, incorrect specimen transport, or specimens outside stability limits. 

Reference Values

 

Test

Reference Range

sFlt/PlGF Ratio

<40

 

Critical Values

Analyte

Unit

Low

High

Age

N/A

N/A

N/A

N/A

N/A

CPT Codes

81599

Volume

Preferred Volume: 1.0 mL

Minimum Volume: 0.5 mL

Specimen Stability

Storage Temperature

Stability

Room temperature

1 day

Refrigerated

14 days

Frozen

6 months 

Freeze only once

Collection Instructions

Collect specimen per standard collection procedures. 

 

Test Components

sFLT-1, PlGF, sFLT-1/PlGF Ratio

Clinical Indications

Interpretation:

  • sFlt1/PlGF ratio <40 has a low probability (<5%) of developing preeclampsia with severe features within 2 weeks.
  • sFlt1/PlGF ratio ≥40 has a high probability of developing preeclampsia with severe features within 2 weeks (positive predictive value of 65%). [This ratio surpassed routine clinical measures. These markers also correlate with adverse maternal outcomes and predict delivery within 2 weeks.]

Disclaimer:           

Management of patients with preeclampsia is based entirely on the discretion of treating physicians.

Methodology

The Thermo Fisher B·R·A·H·M·S sFlt-1 and PlGF plus KRYPTOR are homogeneous sandwich immunoassays for detection of sFlt-1 and PlGF in human serum or plasma.

Additional Information

The sFlt1/PlGF ratio is approved for clinical use by the US FDA in admitted patients with singleton pregnancies (23-34.6 weeks GA).

  • In patients with pre-eclampsia sFlt-1 levels are significantly increased while PlGF levels are significantly decreased compared to healthy pregnancies.
  • The sFlt-1/PlGF ratio is a useful tool as an aid to confirm the diagnosis of pre-eclampsia.
  • The sFlt-1/PlGF ratio improves the predictive value of Doppler ultrasound alone.
  • The sFlt-1/PlGF ratio is useful in the differential diagnosis of hypertensive pregnancy-related disorders.
  • The sFlt-1/PlGF ratio is useful in predicting the development of an adverse outcome in women with diagnosed pre-eclampsia.

The determination of maternal serum sFlt-1 and PlGF together with other biological and clinical data improves the diagnostic possibilities in pre-eclampsia management in second and third trimester of pregnancy.

Turnaround Time

Turnaround times are relative to the time the specimen is received in the test laboratory. 

 

STAT Turnaround Time: Not available as STAT test (see testing schedule below)

Routine Turnaround Time: N/A (see testing schedule below)

Testing Schedule: Batch Testing 7 days a week (7am – 3pm).  Samples received by 12pm will be run the same day, samples received after 12pm will be setup and resulted the following day. 

Last Review Date

4/2/2024

Synonyms/Keyword Search

PECRA

Preeclampsia

sflt-1

PlGF

sflt-1/plgf ratio